Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study on the Immunization Schedule for the 13-Valent Pneumococcal Polysaccharide-Conjugate Vaccine in Healthy Infants
Sponsor: Beijing Center for Disease Control and Prevention
Summary
To compare the immunogenicity of the domestically produced PCV13 vaccine in healthy 2-month-old infants following administration via the 2+1 and 3+1 schedules, with the primary endpoint being the seroprevalence of specific IgG antibodies after completion of the vaccination series.To evaluate the safety of the 2+1 schedule in infants and young children (incidence of adverse events and serious adverse events).
Key Details
Gender
All
Age Range
60 Days - 89 Days
Study Type
INTERVENTIONAL
Enrollment
210
Start Date
2026-05-10
Completion Date
2027-12-31
Last Updated
2026-05-15
Healthy Volunteers
Yes
Conditions
Interventions
the domestically produced 13-valent Pneumococcal Polysaccharide Conjugate vaccine
2, 4, and 12 months vaccination schedule for arm A and 2, 4, 6 and 12 months vaccination schedule for arm B